What is left of adaptive servo-ventilation after the results of the SERVE-HF study?
ଝ
Que reste-t-il de la ventilation auto-asservie après les résultats de l'étude SERVE-HF ?

♦
English version
On May 13, 2015, the first results of the SERVE-HF study have revolutionised the world of practitioners using adaptive servo-ventilation (ASV) for the treatment of central sleep apnoeas occurring as Cheyne-Stokes respiration in the context of systolic heart failure. The aim of this trial was to identify the effects of ASV on the rehospitalisation and mortality rates of symptomatic chronic heart failure patients with impaired left ventricular ejection fraction (LVEF ≤ 45%) and a moderate to severe predominant central sleep apnoea syndrome.
Against all odds, the preliminary results of this study have revealed a significant increase in the risk of cardiovascular death in patients treated with ASV compared to the control group, which only received an optimal medical management. These results are disturbing because these deaths occurred in the absence of any worsening of the cardiovascular status of treated patients, apart from any hospitalisation, as sudden deaths which did not particularly occur during sleep and while ventilation properly managed central sleep apnoeas as expected in the study. This increased risk of cardiovascular mortality was constant over time, regardless of the benefit of the treatment received by the patients, and seems to increase with the severity of the LVEF impairment. These results are destabilising because they contrast with those obtained during the last decade which, although based on small samples of patients and usually obtained in the short term, had provided a growing body of evidence advocating the benefit of the use of ASV in terms of clinical improvement and systolic function in these patients. It will be necessary to further analyse these preliminary Editorial -article in English and French results to better understand the mechanisms, investigate the presence of biases in patient distribution or in their initial inclusion, attempt to better understand the intrinsic role of ventilation, and possibly define ''high-risk phenotypes''. Similarly, many questions have emerged regarding the interest of obtaining a systematic regression of central sleep apnoeas, and their role in the mechanisms of chronic heart failure, apart from demonstrating the severity of the underlying heart failure.
These results have led to a warning from ResMed as a safety information communicated and circulated by the American Association of Sleep Medicine. Secondly, an official communication from ResMed leaders at the American Thoracic Society in Denver, lead to discuss these results with the audience, with the aim to provide all the necessary transparency, and to work together with the learned societies. It is under these conditions that a first joint statement from the Société de pneumologie de langue française (SPLF) and the Société française de recherche et médecine du sommeil (SFRMS) has been released on the website of these two learned societies with the aim of presenting these results objectively, and providing some practical guidelines to follow with these patients.
Nevertheless, it was necessary to give further consideration to these results in order to attempt to respond to all our concerns and questions, faced with the need to take a decision to discontinue ventilation in patients we had seen evolve favourably on treatment, and for whom treatment discontinuation could be considered a loss of chance for improvement, leaving them alone with their disease. Moreover, it was also essential to avoid that these results, obtained in a very precise and very fragile population which is not representative of the majority of current indications of ASV, would be likely to lead to an extent of contraindications toward pathologies with different mechanisms and for which the use of ASV remains fully effective. This is of course the case of the treatment of central sleep apnoeas secondary to stroke or related to a complex sleep apnoea syndrome for example. But this is also the case of heart failure with preserved ejection fraction, which did not fall within the scope of indications for inclusion in the SERVE-HF study.
That is why a group of experts, including pulmonologists, sleep specialists and cardiologists, has been asked to write a position paper-like article whose text is contained in this issue of the Revue des maladies respiratoires (Priou et al. Adaptive servo-ventilation: How does it fit into the treatment of central sleep apnoea syndrome? Expert opinions). Its aim was to review the preliminary results of the SERVE-HF study and their consequences, but also to provide more detailed arguments based on data from the literature advocating the continued use of ASV in targeted indications. This publication has been written in order to enable everyone to find ways to adapt to this new configuration in order to identify ways of providing an optimal treatment to our patients. Moreover, it sets up the foundations for an unprecedented joint work, overcoming the divisions of our specialties, giving us the opportunity to unite around a major topic, in order to provide a solution based on our skill complementarity and our desire to advance our therapeutic management on a daily basis. We should take advantage of it, and continue together this approach demonstrating medical humanism.
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Version française
Les premiers résultats de l'étude SERVE-HF ont donné lieu, le 13 mai 2015, à un véritable coup de tonnerre dans le ciel jusque-là serein des praticiens utilisant la ventilation auto-asservie pour le traitement des apnées centrales survenant sous la forme d'une respiration de Cheyne-Stokes dans le cadre d'une insuffisance cardiaque systolique. Cet essai avait pour but d'identifier les effets de ce type de ventilation sur le taux de ré-hospitalisation et le taux de mortalité des patients insuffisants cardiaques chroniques symptomatiques avec altération de la fraction d'éjection du ventricule gauche (FEVG ≤ 45 %) et un syndrome d'apnées du sommeil central prédominant modéré à sévère.
Contre toute attente, les résultats préliminaires de cette étude ont révélé une augmentation significative du risque de décès cardiovasculaires chez ces patients traités par ventilation auto-asservie par rapport au groupe de patients contrôle bénéficiant uniquement d'une prise en charge médicale optimale. Ces résultats sont d'autant plus troublants que ces décès sont survenus en l'absence de toute aggravation de l'état cardiovasculaire des patients sous traitement, en dehors de toute hospitalisation, sous la forme de morts subites ne survenant pas particulièrement au cours du sommeil, et alors que la ventilation traitait correctement les apnées centrales comme attendu dans l'étude. Ce risque accru de mortalité cardiovasculaire était constant dans le temps, indépendamment du bénéfice de la thérapie perçu par le patient, et semble augmenter avec la sévérité de l'altération de la FEVG. Ces résultats sont d'autant plus déstabilisant qu'ils sont en opposition avec ceux obtenus au cours de la dernière décennie qui, bien que reposant sur de faibles échantillons de patients et généralement à court terme, avaient apporté un faisceau d'arguments en faveur de l'utilisation de cette ventilation auto-asservie sur l'amélioration clinique et de la fonction systolique de ces patients. Il sera indispensable d'approfondir l'analyse de ces résultats préliminaires afin de mieux en comprendre les mécanismes, rechercher la présence de biais dans la répar-tition des patients ou dans leur inclusion initiale, tenter de mieux comprendre le rôle intrinsèque de la ventilation et définir éventuellement des « phénotypes à risque ». De même, de nombreuses interrogations sont apparues concernant l'intérêt d'obtenir une régression systéma-tique de ces apnées centrales, et leur place dans les mécanismes de l'insuffisance cardiaque chronique, en dehors du fait de témoigner de la sévérité de l'insuffisance cardiaque sous-jacente.
Ces résultats ont donné lieu à une alerte de la part de la société ResMed sous la forme d'une information de sécu-rité relayée et diffusée par l'American Association of Sleep Medicine. Lors de l'American Thoracic Society à Denver, une seconde communication officielle a été faite par des
